Compare ATOM & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | PLX |
|---|---|---|
| Founded | 2001 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 182.9M |
| IPO Year | 2016 | 1996 |
| Metric | ATOM | PLX |
|---|---|---|
| Price | $3.80 | $2.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 391.4K | ★ 767.5K |
| Earning Date | 10-27-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $62,000.00 | ★ $52,744,000.00 |
| Revenue This Year | $361.54 | $55.77 |
| Revenue Next Year | $233.33 | N/A |
| P/E Ratio | ★ N/A | $10.30 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $1.60 |
| 52 Week High | $12.37 | $3.19 |
| Indicator | ATOM | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 57.33 |
| Support Level | $3.46 | $2.59 |
| Resistance Level | $4.97 | $2.85 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 9.96 | 73.83 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.